Claim OwnershipVJNeurology Podcast
Subscribed: 2Played: 31
Subscribe
© Copyright 2022 All rights reserved.
Description
The Video Journal of Neurology (VJNeurology) podcast covers the latest neurology news from international experts - from Parkinson’s disease, multiple sclerosis, to epilepsy, stroke and headache. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinions. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjneurology.com
47 Episodes
Reverse
This episode focuses on key updates in multiple sclerosis (MS) research from the 11th Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum. We begin with key trial updates, including the FENtrepid (NCT04544449) and MoonStone (NCT06564311) results presented by Amit Bar-Or, MD, FRCPC, University of Pennsylvania, Philadelphia, PA. Le Hanh Hua, MD, Cleveland Clinic, Las Vegas, NV, then discusses a secondary analysis of the OLIKOS study (NCT04486716), and Jeffrey Cohen, MD, Cleveland Clinic, Cleveland, OH, introduces the use of hematopoietic stem cell transplantation.
Novel technologies are discussed by Gianmarco Bellucci, MD, PhD, University of California, San Francisco, CA, Raphael Schneider, MD, PhD, FRCPC, CIP, St. Michael’s Hospital, Toronto, Canada, and Valentina Fossati, PhD, The Jackson Laboratory, New York, NY. Finally, Gary Cutter, MS, PhD, UAB School of Public Health, Birmingham, AL, shares the limitations of using brain atrophy measured by MRI as a clinical trial endpoint, and Dalia Rotstein, MD, University of Toronto, Toronto, Canada, discusses a study that found that MS onset precedes EBV infection in some cases.
In this episode of the VJNeurology podcast, we are joined by Prof. Mona Nada, MBBCh, MD, Cairo University, Cairo, Egypt, to discuss updates in the prevention, diagnosis, and treatment of cluster headache. Cluster headache is a rare but devastating primary headache disorder, often described as one of the most severe pain conditions in medicine. Characterized by recurrent attacks of severe unilateral head pain, accompanied by autonomic symptoms such as lacrimation and nasal congestion, it has a profound impact on patients’ quality of life. Despite this, cluster headache remains under-recognised and challenging to treat, making ongoing research and expert clinical insight essential.
This episode of the VJNeurology Podcast focuses on the impact of climate change and temperature fluctuations on the management of epilepsy. Anita Arsovska, MD, PhD, University “Ss Cyril and Methodius”, Skopje, North Macedonia, and Medine Gulcebi Idriz Oglu, MD, Marmara University, Istanbul, Turkey, delve into the effects of rising temperatures on seizure frequency, the supply chains of anti-seizure medication, the stability of anti-seizure medication, and adverse reactions to medication.
In this episode of the VJNeurology Podcast, Jeffrey Dunn, MD, Stanford University School of Medicine, Palo Alto, CA, shares insights from a Phase I trial (NCT06138132) of CAR T-cell therapy for multiple sclerosis (MS). CAR T-cell therapy is a form of adoptive cell transfer that has revolutionized hematologic oncology and is now being investigated as a targeted immunotherapeutic approach for autoimmune diseases such as MS. Prof. Dunn will delve into the mechanism of action of CAR-T in MS and share findings from the trial.
In this episode of the VJNeurology Podcast, we’re joined by Krystof Bankiewicz, MD, PhD, The Ohio State University, Columbus, OH, to explore the evolving role of gene therapy in Parkinson’s disease and other neurological disorders. Dr Bankiewicz provides an insightful overview of gene therapies currently in clinical development, highlighting emerging efficacy and safety data from ongoing trials. He also delves into the selection of appropriate candidates for these treatments and discusses how close we are to translating these advances into routine clinical care.
In this podcast episode, leading experts Kara Melmed (NYU Langone Health, New York City, NY) and Chitra Venkatasubramanian (Stanford University, Stanford, CA) debate blood pressure targets in ICH, focusing on the key question: how low should we go? They discuss the pathophysiological background for lowering blood pressure in ICH, key trial evidence, selecting between agents, and give advice for practicing clinicians.
Welcome to today's podcast, which focuses on the understanding and management of rare brain disorders. This episode, in honor of Rare Disease Day, delves into a variety of rare neurological conditions, including adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), phenylketonuria (PKU), cerebral autosomal dominant arteriopathy with subcortical infarct (CADASIL), succinic semialdehyde dehydrogenase deficiency (SSADHD), and rare epilepsies.
This podcast features Zbigniew Wszolek, MD, Mayo Clinic, Jacksonville, FL, Bernadette Sheehan Gilroy, PhD candidate and rare disease advocate, Munster Technological University, Kerry, Ireland, Elisa Ferrante, PhD, National Institutes of Health, Bethesda, MD, Christian Brandt, MD, Bielefeld University Medical School, Bielefeld, Germany, Simona Balestrini, MD, PhD, University College London, London, UK, and Henry Lee, PhD, Boston Children’s Hospital, Boston, MA.
The 2024 revision of the McDonald diagnostic criteria for multiple sclerosis (MS) was recently presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2024). Key updates include the recognition of optic nerve lesions, the incorporation of cerebrospinal fluid (CSF) kappa-free light chains as a diagnostic biomarker, and the addition of central vein sign (CVS) and paramagnetic rim lesions (PRLs) as imaging markers.
This podcast features experts Marcello Moccia, MD, PhD, University of Naples Federico II, Naples, Italy, Serena Borrelli, MD, Université catholique de Louvain & Hôpital Erasme, Université Libre de Brussels, Brussels, Belgium, Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, and Giancarlo Comi, MD, Vita-Salute San Raffaele University, Milan, Italy, who discuss the updates. They delve into the diagnostic value of CVS, PRLs, and optic nerve lesions, and speak about the implementation of these new guidelines into clinical practice.
Dopaminergic medications have been widely used in the treatment of restless legs syndrome (RLS), where they are effective at reducing symptoms in the short term. However, long-term use of these agents has been associated with augmentation, a worsening of symptoms over time or earlier in the day. This phenomenon has led to a shift in treatment recommendations, favoring non-dopaminergic options as first-line therapies.
This podcast brings you updates on managing augmentation in RLS from Sleep Europe 2024, which took place in Seville, Spain. You will hear from experts Celia Garcia-Malo, MD, PhD, Centro Integral de Sueño y Neurociencias CISNe, Madrid, Spain, Diego Garcia-Borreguero, MD, PhD, Sleep Research Institute, Madrid, Spain, and Ambra Stefani, MD, PhD, Medical University of Innsbruck, Innsbruck, Austria. They delve into the role of dopaminergic agonists in the treatment of RLS and how augmentation can develop. They suggest various alternative therapies, give advice for terminating dopaminergic agents, and provide updates on guidelines regarding the use of dopaminergic therapies.
In recent years, genetic therapies have garnered much attention for their potential to modify the underlying pathological processes in neurological diseases. By correcting, replacing, or removing aberrant genetic material, gene therapies could revolutionize the treatment of many diseases, where symptomatic management is the only available option.
Examples of gene therapy methods include the use of CRISPR/Cas9 technologies to directly edit genetic mutations, vector-based gene therapy to deliver new genetic material, and antisense oligonucleotides (ASOs) to modulate gene expression.
The success of gene therapy in treating diseases like spinal muscular atrophy (SMA) has paved the way for similar approaches in amyotrophic lateral sclerosis (ALS), with several groundbreaking clinical trials taking place in recent years.
In this podcast, we are joined by leading neurologist Prof. Dame Pamela Shaw who will share her insights into the progress in genetic therapies for ALS and explain the challenges being faced, offering a glimpse into the future ALS therapy landscape.
With Prof. Dame Pamela Shaw, DBE, MBBS, MD, FRCP, FMedSci, FAAN, FANA, FAAAS, University of Sheffield, Sheffield, UK.
In this episode, we delve into the complexities of managing status epilepticus, particularly the refractory stages that resist initial treatments. Status epilepticus is a neurological emergency that requires prompt medical intervention to prevent significant morbidity and mortality. Despite aggressive treatment, some cases do not respond to initial lines of therapy. Refractory and super refractory status epilepticus pose significant treatment challenges and carry high risks, including neuronal injury, long-term neurological deficits, and increased mortality.
Tune in to learn more about the approaches to refractory and super refractory status epilepticus management, novel strategies that are gaining traction, unique considerations in the pediatric population, and new research looking at biomarkers in new-onset refractory status epilepticus (NORSE) to predict short- and long-term outcomes.
With Clio Rubinos, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC; Maria Roberta Cilio, MD, PhD, Université Catholique de Louvain,
Brussels, Belgium; and Aurelie Hanin, PharmD, PhD, Yale University, New
Haven, CT.
Welcome to this episode of the VJ Sounds Podcast, brought to you by the Video Journal of Neurology (VJNeurology). In this podcast, we discuss the important subject of medication overuse headache (MOH). Discover insights into key debates in the field from renowned experts, Prof. Sait Ashina from Harvard Medical School, Prof. Morris Levin from the University of California, San Francisco, Alan Rappaport, University of California, Los Angeles, and Licia Grazzi, Fondazione IRRCS Istituto Neurologico Carlo Besta.
The latest guidelines recommend endovascular thrombectomy (EVT) as the gold standard treatment approach for eligible patients with an acute ischemic stroke due to large vessel occlusion, but there is currently no robust randomized control data supporting its routine use in medium vessel occlusion (MeVO) strokes.
In this podcast, stroke experts delve into current uncertainties surrounding the management of small- and medium-vessel strokes, namely optimal detection and treatment strategies. They discuss current guidelines, key debates, and ongoing randomized clinical trials assessing the efficacy of EVT in MeVO stroke.
With Johanna Ospel, MD, University of Calgary, Alberta, Canada; Nishita Singh, MD, University of Calgary, Alberta, Canada; and Jan Gralla, MD, Inselspital, University Hospital Bern, Bern, Switzerland.
Welcome to our latest episode of the Video Journal of Neurology podcast where we explore the rapidly evolving world of precision medicine within the field of epilepsy. In this episode, we delve into how our emerging understanding of genetic factors is reshaping our knowledge of epilepsy syndromes, shedding light on personalized treatment strategies.
Join us as Guido Rubboli, MD; Simona Balestrini, MD, PhD; Reetta Kälviäinen, MD, PhD; and Kristen Park, MD, share their invaluable perspectives on the cutting-edge advancements in precision medicine for epilepsy. Together, they unravel key advances, including the use of pharmacogenomics for decision making, the development of gene therapies, and the role of gene modifiers in phenotypic expression.
We hope you enjoy listening and find this episode useful.
Cluster headache, a rare and severe headache disorder, represents the
most common trigeminal autonomic cephalalgia. Due to its rarity and often refractory nature, management can be challenging.
In this episode, leading experts delve into acute and preventive treatment strategies for cluster headache. Emerging therapies are also discussed, including psilocybin and CGRP-targeted agents.
In this podcast, key opinion leaders Hans Lassman, MD, Medical University of Vienna; Vyanka Redenbaugh, MD, Mayo Clinic College of Medicine; Torge Rempe, MD, PhD, University of Florida College of Medicine; and Kazuo Fujihara, MD, PhD, Fukushima Medical University School of Medicine, give a comprehensive overview of the current research landscape in MOGAD, including its differentiation from MS, diagnostic techniques, predictors of relapse, and an ongoing clinical trial investigating an interleukin-6 targeted monoclonal antibody in the treatment of relapsing MOGAD.
In this podcast, Tiago Outeiro, PhD, University Medical Center Göttingen, Göttingen, Germany; Chia-Chun Chiang, MD, Mayo Clinic, Rochester, MN; and Daniel Goldenholz, MD, PhD, Beth Israel Deaconess Medical Center, Boston, MA, engage in a thought-provoking discussion on the latest developments in AI application. They explore how AI's predictive capabilities could revolutionize basic science, its potential role in the diagnosis and treatment of headache disorders, and the current and prospective uses of AI across different fields of neurology.
Join us in this exciting exploration of AI's potential to reshape neurology, its existing successes, and the exciting opportunities it holds for the future.
Neurologists and researchers are increasingly harnessing the power of wearables to gather real-time, high-quality data about patients' neurological conditions.
We are joined by leading neurology experts who will share their insights into the diverse applications of wearables in the fields of epilepsy, movement disorders, multiple sclerosis and sleep disorders, offering a glimpse into the future of neurology.
The causative nature of alpha-synuclein (ɑ-syn) accumulation in Parkinson's disease (PD) pathophysiology has been a subject of debate among researchers, ever since its identification in Lewy bodies.
In this episode, experts discuss our current understanding of the role of ɑ-syn in PD, as well as the possibility that the loss of normal ɑ-syn function may be more relevant than the accumulation of insoluble ɑ-syn. We will hear from researchers working to improve the diagnosis and monitoring of PD, with the exciting development of novel ɑ-syn-PET tracers and seed amplification assays that can detect early PD with high sensitivity and specificity.
Biomarker development and discovery have been an important point in multiple sclerosis (MS) research for many years.
In this podcast, Elias Sotirchos, MD, Johns Hopkins University School of Medicine, Baltimore, MD; Ferhan Qureshi, VP – Biomarker Product Development, Octave, Menlo Park, CA; and Shane Arsenault, MD, Memorial University of Newfoundland, St. John’s, Canada, discuss recent updates on the development and validation of biomarkers that can predict disability progression, monitor ongoing disease activity, and assess treatment response.
Comments
Download from Google Play
Download from App Store
United States